Literature DB >> 17418946

A novel adenoviral vector-mediated neuronal selective gene expression in neonatal mouse brain in response to hypoxia.

Sheng T Hou1, Susan X Jiang, Deqi Huang, Angele Desbois.   

Abstract

Selective gene expression targeting neurons is a challenge, which, if successfully overcome, carries an enormous potential for clinical applications in therapeutics against neurodegenerative diseases. We have reported previously the construction of a series of adenoviral vectors capable of selectively expressing a reporter gene luciferase in cultured neurons [D. Huang, A. Desbois, S.T. Hou, A novel adenoviral vector which mediates hypoxia-inducible gene expression selectively in neurons, Gene Ther. 12 (2005) 1369-1376]. A combination of neuron restrictive silencer elements (NRSEs), hypoxia responsive elements (HREs) and CMV minimal promoter (CMVmp) was packaged into replication defective adenovirus to target gene expression selectively in neurons in a hypoxia-regulated manner. In the present study, we injected the adenoviral vectors into the neonatal mouse brain followed by treatment with hypoxia. The expression of the reporter luciferase gene was examined by luciferase assay and fluorescent immunostaining. Neurons and glial cells were identified by staining with antibodies against NeuN and GFAP, respectively. Remarkably, in response to hypoxia, Ad/5HRE-3NRSE showed strong hypoxia-inducible gene expression of the reporter luciferase selectively in neurons but not in glial cells. In contrast, brains infected with the control vector Ad/5HRE showed no selectivity in luciferase expression (in both neurons and glial cells) under the hypoxic condition. Taken together, these studies demonstrated that this vector (Ad/5HRE-3NRSE) can mediate gene expression selectively in neurons both in vitro and in vivo, supporting the suggestion that further refinement of this vector may lead to the development of a useful tool to investigate mechanisms of neuronal damage following cerebral ischemia and a possible effective gene therapy vector to stroke.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17418946     DOI: 10.1016/j.neulet.2007.03.059

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  4 in total

1.  Gene regulation systems for gene therapy applications in the central nervous system.

Authors:  Jerusha Naidoo; Deborah Young
Journal:  Neurol Res Int       Date:  2012-01-05

2.  Semaphorin3A elevates vascular permeability and contributes to cerebral ischemia-induced brain damage.

Authors:  Sheng Tao Hou; Ladan Nilchi; Xuesheng Li; Sandhya Gangaraju; Susan X Jiang; Amy Aylsworth; Robert Monette; Jacqueline Slinn
Journal:  Sci Rep       Date:  2015-01-20       Impact factor: 4.379

Review 3.  Neonatal Hypoxia Ischaemia: Mechanisms, Models, and Therapeutic Challenges.

Authors:  Lancelot J Millar; Lei Shi; Anna Hoerder-Suabedissen; Zoltán Molnár
Journal:  Front Cell Neurosci       Date:  2017-05-08       Impact factor: 5.505

4.  Adenovector GAD65 gene delivery into the rat trigeminal ganglion produces orofacial analgesia.

Authors:  Jean-Philippe Vit; Peter T Ohara; Christopher Sundberg; Blanca Rubi; Pierre Maechler; Chunyan Liu; Mariana Puntel; Pedro Lowenstein; Maria Castro; Luc Jasmin
Journal:  Mol Pain       Date:  2009-08-05       Impact factor: 3.395

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.